Gene test may guide myeloma treatment in new study
NCT ID NCT07514052
First seen May 03, 2026 · Last updated May 24, 2026 · Updated 6 times
Summary
This study looks at whether certain genes can predict how well the drug selinexor works for people with multiple myeloma that has come back or stopped responding to treatment. About 127 adults will receive selinexor plus standard drugs, and researchers will track their response and survival for up to 2 years. The goal is to find gene markers that help doctors choose the best treatment for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA OF BONE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ShanxiBethuneH
RECRUITINGTaiyuan, Shanxi, 030000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.